ConductScience.org, home

Paper28297622

Clinical Trials in the Genomic Era.

Joffe E and 2 others. J Clin Oncol, 2017. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Clinical Trials in the Genomic Era. Papers, record 28297622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28297622

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical Trials in the Genomic Era.
PubMed
Journal
J Clin Oncol
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
0.36
iCite
Revised in PubMed
2024-06-04
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Joffe EErel
2Iasonos AAlexia
3Younes AAnas

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Clinical Trials as TopicMajor topic
GenomicsMajor topic
NeoplasmsMajor topic
Humans
Molecular Targeted Therapy

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122375970JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.N Engl J Med2012https://conductscience.org/library/papers/22375970PubMed
227083333Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.Lancet Oncol2016https://conductscience.org/library/papers/27083333PubMed
321639808Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med2011https://conductscience.org/library/papers/21639808PubMed
426466571Mutations driving CLL and their evolution in progression and relapse.Nature2015https://conductscience.org/library/papers/26466571PubMed
526287849Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.N Engl J Med2015https://conductscience.org/library/papers/26287849PubMed
627214515Genomic Alteration-Driven Clinical Trial Designs in Oncology.Ann Intern Med2016https://conductscience.org/library/papers/27214515PubMed
726941398BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.Blood2016https://conductscience.org/library/papers/26941398PubMed
826282654Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.J Clin Oncol2015https://conductscience.org/library/papers/26282654PubMed
924030381Clinical and biological implications of driver mutations in myelodysplastic syndromes.Blood2013https://conductscience.org/library/papers/24030381PubMed
1027893325Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.J Clin Oncol2017https://conductscience.org/library/papers/27893325PubMed
1125805592Novel targeted therapies in diffuse large B-cell lymphoma.Semin Hematol2015https://conductscience.org/library/papers/25805592PubMed
1221931113Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood2011https://conductscience.org/library/papers/21931113PubMed
1325810246The Signature Program: Bringing the Protocol to the Patient.Clin Pharmacol Ther2015https://conductscience.org/library/papers/25810246PubMed
1425726955Management of adverse events associated with idelalisib treatment: expert panel opinion.Leuk Lymphoma2015https://conductscience.org/library/papers/25726955PubMed
1526342236
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol2015https://conductscience.org/library/papers/26342236PubMed
1623144193Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.Haematologica2013https://conductscience.org/library/papers/23144193PubMed
1722258401Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.Leukemia2012https://conductscience.org/library/papers/22258401PubMed
1824615778A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).Blood2014https://conductscience.org/library/papers/24615778PubMed
1927197177Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.Cancer Res2016https://conductscience.org/library/papers/27197177PubMed
2027167109A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.Oncotarget2016https://conductscience.org/library/papers/27167109PubMed

See all 60 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
40873988Scanning the horizon of personalized prevention research: an overview of ongoing European funded initiatives.Front Public Health2025https://conductscience.org/library/papers/40873988PubMed
40156702The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Curr Oncol Rep2025https://conductscience.org/library/papers/40156702PubMed
38357305From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.Front Pharmacol2024https://conductscience.org/library/papers/38357305PubMed
36929083Pharmacogenomic and Statistical Analysis.Methods Mol Biol2023https://conductscience.org/library/papers/36929083PubMed
34197637Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.Clin Pharmacol Ther2022https://conductscience.org/library/papers/34197637PubMed
31337605Challenges and approaches to implementing master/basket trials in oncology.Blood Adv2019https://conductscience.org/library/papers/31337605PubMed
29895903Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.Blood Cancer J2018https://conductscience.org/library/papers/29895903PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28297622

GET https://conductscience.org/api/papers/v1/28297622/references?page=2